MedTrace Logo

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

NCT05765578 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1713

Last updated 2024-07-31

No results posted yet for this study

Summary

The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).

Conditions

Interventions

BIOLOGICAL

Moderna COVID-19 Vaccine

Sterile liquid for injection. Intervention not administered through this study.

BIOLOGICAL

Moderna mRNA1273.222 Booster

Sterile liquid for injection. Intervention not administered through this study.

BIOLOGICAL

Pfizer COVID-19 Vaccine

Sterile liquid for injection. Intervention not administered through this study.

BIOLOGICAL

Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)

Sterile liquid for injection. Intervention not administered through this study.

BIOLOGICAL

Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)

Sterile liquid for injection. Intervention not administered through this study.

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-08
Primary Completion
2024-06-17
Completion
2024-06-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05765578 on ClinicalTrials.gov